CD3 binding molecules

US12460002B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-12460002-B2
Application numberUS-202017438768-A
CountryUS
Kind codeB2
Filing dateMar 27, 2020
Priority dateMar 29, 2019
Publication dateNov 4, 2025
Grant dateNov 4, 2025

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to heavy chain variable regions, binding domains and antibodies specific for human CD3, and CD3 binding proteins. The invention further relates to the use of a CD3 binding protein, preferably an antibody, of the invention in the treatment of cancer or autoimmune disease.

First claim

Opening claim text (preview).

The invention claimed is: 1 . An antigen-binding protein that binds human CD3 comprising an antibody variable domain comprising a heavy chain variable region and a light chain variable region wherein the heavy chain variable region comprises: a CDR1, CDR2 and CDR3 comprising the amino acid sequence: CDR1:  (SEQ ID NO: 42) SFGIS CDR2:  (SEQ ID NO: 43) GFIPVLGTANYAQKFQG  CDR3:  (SEQ ID NO: 44) RGNWNPFDP; or comprising the amino acid sequence: CDR1:  (SEQ ID NO: 51) SKTFTIS; CDR2:  (SEQ ID NO: 52) GIIPLFGTITYAQKFQG; CDR3:  (SEQ ID NO: 53) RGNWNPFDP; or comprising the amino acid sequence: CDR1:  (SEQ ID NO: 60) SRTFTIS; CDR2:  (SEQ ID NO: 61) SIIPIFGTITYAQKFQG; CDR3: (SEQ ID NO: 62) RGNWNPFDP; or comprising the amino acid sequence: CDR1:  (SEQ ID NO: 84) SKTLTIS; CDR2:  (SEQ ID NO: 85) GIIPIFGSITYAQKFQD; CDR3:  (SEQ ID NO: 86) RGNWNPFDP, or comprising the amino acid sequence: CDR1:  (SEQ ID NO: 68) GSGIS; CDR2:  (SEQ ID NO: 69) GFIPFFGSANYAQKFRD; CDR3:  (SEQ ID NO: 70) RGNWNPLDP; or comprising the amino acid sequence: CDR1: (SEQ ID NO: 100) GSGIS; CDR2: (SEQ ID NO: 101) GFIPFFGSANYAQKFRD; CDR3:  (SEQ ID NO: 102) RGNWNPFDP; or comprising the amino acid sequence: CDR1:  (SEQ ID NO: 199) RFWIG; CDR2:  (SEQ ID NO: 200) IIYPGDSDTRYSPSFQG; CDR3:

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US12460002B2 cover?
The invention relates to heavy chain variable regions, binding domains and antibodies specific for human CD3, and CD3 binding proteins. The invention further relates to the use of a CD3 binding protein, preferably an antibody, of the invention in the treatment of cancer or autoimmune disease.
Who is the assignee on this patent?
Merus Nv
What technology area does this patent fall under?
Primary CPC classification C07K16/2863. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Nov 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).